Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• Reduced expression in immortalized cells (REIC)/dickkopf-3 (Dkk-3) is a tumor suppressor gene downregulated in various cancers.
• Previous studies demonstrated REIC/Dkk-3's tumor-inhibitory effects in pancreatic cancer via conventional adenoviral vectors (Ad-CAG-REIC).

Purpose of the Study:

• To develop and evaluate a novel Ad-REIC vector utilizing a super gene expression (SGE) system for enhanced pancreatic cancer therapy.
• To compare the therapeutic efficacy of the Ad-SGE-REIC vector against the conventional Ad-CAG-REIC vector.

Main Methods:

• Human pancreatic cancer cell lines (ASPC1, MIAPaCa2) were treated with Ad-SGE-REIC and Ad-CAG-REIC vectors.
• REIC/Dkk-3 protein expression was quantified using western blot analysis.
• In vitro cell viability and apoptosis assays were performed, alongside in vivo mouse xenograft models to assess anti-tumor effects.

Main Results:

• Ad-SGE-REIC significantly increased REIC protein expression compared to Ad-CAG-REIC.
• Ad-SGE-REIC demonstrated superior inhibition of cell viability and greater induction of apoptosis in pancreatic cancer cell lines.
• The Ad-SGE-REIC vector achieved more effective tumor growth inhibition in the mouse xenograft model than Ad-CAG-REIC.

Conclusions:

• The super gene expression (SGE) system enhances REIC/Dkk-3 delivery and efficacy for pancreatic cancer treatment.
• Ad-SGE-REIC represents an innovative and more effective therapeutic tool compared to conventional adenoviral vectors for pancreatic cancer.